Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
18 Jun 2021
18 Jun 2021
Historique:
received:
23
11
2020
accepted:
24
05
2021
entrez:
19
6
2021
pubmed:
20
6
2021
medline:
20
6
2021
Statut:
epublish
Résumé
Human malaria affects the vast majority of the world's population with the Plasmodium falciparum species causing the highest rates of morbidity and mortality. With no licensed vaccine and leading candidates achieving suboptimal protection in the field, the need for an effective immunoprophylactic option continues to motivate the malaria research community to explore alternative technologies. Recent advances in the mRNA discipline have elevated the long-neglected platform to the forefront of infectious disease research. As the immunodominant coat protein of the invasive stage of the malaria parasite, circumsporozoite protein (PfCSP) was selected as the antigen of choice to assess the immunogenic and protective potential of an mRNA malaria vaccine. In mammalian cell transfection experiments, PfCSP mRNA was well expressed and cell associated. In the transition to an in vivo murine model, lipid nanoparticle (LNP) encapsulation was applied to protect and deliver the mRNA to the cell translation machinery and supply adjuvant activity. The immunogenic effect of an array of factors was explored, such as formulation, dose, number, and interval of immunizations. PfCSP mRNA-LNP achieved sterile protection against infection with two P. berghei PfCSP transgenic parasite strains, with mRNA dose and vaccination interval having a greater effect on outcome. This investigation serves as the assessment of pre-erythrocytic malaria, PfCSP mRNA vaccine candidate resulting in sterile protection, with numerous factors affecting protective efficacy, making it a compelling candidate for further investigation.
Identifiants
pubmed: 34145286
doi: 10.1038/s41541-021-00345-0
pii: 10.1038/s41541-021-00345-0
pmc: PMC8213722
doi:
Types de publication
Journal Article
Langues
eng
Pagination
84Références
Joy, D. A. et al. Early origin and recent expansion of Plasmodium falciparum. Science 300, 318–21 (2003).
pubmed: 12690197
doi: 10.1126/science.1081449
Organization, G.W.H., World malaria report 2019. 2019.
Group, M.V.F., Malaria Vaccine Technology Roadmap. 2013.
Olotu, A. et al. Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children. N. Engl. J. Med. 374, 2519–29 (2016).
pubmed: 27355532
pmcid: 4962898
doi: 10.1056/NEJMoa1515257
McCoy, M. E. et al. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine. Malar. J. 12, 136 (2013).
pubmed: 23607541
pmcid: 3765086
doi: 10.1186/1475-2875-12-136
Kaba, S. A. et al. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS ONE 7(10), e48304 (2012).
pubmed: 23144750
pmcid: 3483151
doi: 10.1371/journal.pone.0048304
Langowski, M. D. et al. Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform. Proc. Natl Acad. Sci. USA 117, 3114–3122 (2020).
pubmed: 31988134
doi: 10.1073/pnas.1911792117
pmcid: 7022184
Genito, C. J. et al. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. Vaccine 35, 3865–3874 (2017).
pubmed: 28596090
doi: 10.1016/j.vaccine.2017.05.070
Cawlfield, A. et al. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). Vaccine 37, 3793–3803 (2019).
pubmed: 31151801
doi: 10.1016/j.vaccine.2019.05.059
Martin, M. L. et al. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin. Malar. J. 18, 377 (2019).
pubmed: 31775762
pmcid: 6880475
doi: 10.1186/s12936-019-3014-5
Espinosa, D.A. et al. Robust antibody and CD8(+) T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection. NPJ Vaccines 2, 10 https://doi.org/10.1038/s41541-017-0011-y (2017)
Noe, A. R. et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate. PLoS ONE 9, e107764 (2014).
pubmed: 25247295
pmcid: 4172688
doi: 10.1371/journal.pone.0107764
Janitzek, C. M. et al. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses. Malar. J. 15, 545 (2016).
pubmed: 27825348
pmcid: 5101663
doi: 10.1186/s12936-016-1574-1
Khan, F. et al. Head-to-Head Comparison of Soluble vs. Qbeta VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses. PLoS ONE 10, e0142035 (2015).
pubmed: 26571021
pmcid: 4646581
doi: 10.1371/journal.pone.0142035
Wang, R. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476–80 (1998).
pubmed: 9774275
doi: 10.1126/science.282.5388.476
Ferraro, B. et al. Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. Infect. Immun. 81, 3709–20 (2013).
pubmed: 23897618
pmcid: 3811783
doi: 10.1128/IAI.00180-13
Pardi, N. et al. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).
pubmed: 29326426
pmcid: 5906799
doi: 10.1038/nrd.2017.243
Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456–64 (2015).
pubmed: 26050989
pmcid: 4817881
doi: 10.1038/mt.2015.103
Anderson, B. R. et al. Nucleoside modifications in RNA limit activation of 2’-5’-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 39, 9329–38 (2011).
pubmed: 21813458
pmcid: 3241635
doi: 10.1093/nar/gkr586
Midoux, P. & Pichon, C. Lipid-based mRNA vaccine delivery systems. Exp. Rev. Vaccines 14, 221–34 (2015).
doi: 10.1586/14760584.2015.986104
Tam, Y. Y. et al. Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. Nanomedicine 9, 665–74 (2013).
pubmed: 23219877
doi: 10.1016/j.nano.2012.11.006
Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control Release 217, 345–51 (2015).
pubmed: 26264835
pmcid: 4624045
doi: 10.1016/j.jconrel.2015.08.007
Hekele, A. et al. Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect. 2, e52 (2013).
pubmed: 26038486
pmcid: 3821287
doi: 10.1038/emi.2013.54
Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316–1327 (2017).
pubmed: 28457665
pmcid: 5475249
doi: 10.1016/j.ymthe.2017.03.035
Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med 215, 1571–1588 (2018).
pubmed: 29739835
pmcid: 5987916
doi: 10.1084/jem.20171450
Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017).
pubmed: 28151488
pmcid: 5344708
doi: 10.1038/nature21428
Lutz, J. et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2, 29 (2017).
pubmed: 29263884
pmcid: 5648897
doi: 10.1038/s41541-017-0032-6
Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819–29 (2013).
pubmed: 23984729
doi: 10.1056/NEJMoa1208760
O’Garra, A. & Vieira, P. T(H)1 cells control themselves by producing interleukin-10. Nat. Rev. Immunol. 7, 425–8 (2007).
pubmed: 17525751
doi: 10.1038/nri2097
Mosser, D. M. & Zhang, X. Interleukin-10: new perspectives on an old cytokine. Immunol. Rev. 226, 205–18 (2008).
pubmed: 19161426
pmcid: 2724982
doi: 10.1111/j.1600-065X.2008.00706.x
Chaudhury, S. et al. Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis. Sci. Rep. 7, 7998 (2017).
pubmed: 28801554
pmcid: 5554171
doi: 10.1038/s41598-017-08526-5
Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114–1125 e10 (2017).
pubmed: 28222903
pmcid: 5388441
doi: 10.1016/j.cell.2017.02.017
Leitner, W. W., Bergmann-Leitner, E. S. & Angov, E. Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy. Malar. J. 9, 145 (2010).
pubmed: 20507620
pmcid: 2904356
doi: 10.1186/1475-2875-9-145
Dobano, C. et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nat. Commun. 10, 2174 (2019).
pubmed: 31092823
pmcid: 6520358
doi: 10.1038/s41467-019-10195-z
White, M. T. et al. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect. Dis. 15, 1450–8 (2015).
pubmed: 26342424
pmcid: 4655306
doi: 10.1016/S1473-3099(15)00239-X
Maruggi, G. et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35, 361–368 (2017).
pubmed: 27939014
doi: 10.1016/j.vaccine.2016.11.040
Bogers, W. M. et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J. Infect. Dis. 211(6), 947–55 (2015).
pubmed: 25234719
doi: 10.1093/infdis/jiu522
Joe, P. T. et al. Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice. J. Transl. Med. 17(1), 242 (2019).
pubmed: 31345237
pmcid: 6659201
doi: 10.1186/s12967-019-1991-3
Pascolo, S. Synthetic messenger RNA-based vaccines: from scorn to hype. Viruses 13, 2 (2021).
doi: 10.3390/v13020270
Fu, T. M. et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med. 3, 362–71 (1997).
pubmed: 9234241
pmcid: 2230213
doi: 10.1007/BF03401683
Lazzaro, S. et al. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology 146, 312–26 (2015).
pubmed: 26173587
pmcid: 4582972
doi: 10.1111/imm.12505
Kauffman, K. J., Webber, M. J. & Anderson, D. G. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J. Control Release 240, 227–234 (2016).
pubmed: 26718856
doi: 10.1016/j.jconrel.2015.12.032
De Beuckelaer, A. et al. Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses. Mol. Ther. 24, 2012–2020 (2016).
pubmed: 27506450
pmcid: 5154477
doi: 10.1038/mt.2016.161
Pollard, C. et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 21, 251–9 (2013).
pubmed: 23011030
doi: 10.1038/mt.2012.202
Tsui, N. B., Ng, E. K. & Lo, Y. M. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin. Chem. 48, 1647–53 (2002).
pubmed: 12324479
doi: 10.1093/clinchem/48.10.1647
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
pubmed: 33378609
doi: 10.1056/NEJMoa2035389
Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11–21 (2018).
pubmed: 29972753
doi: 10.1056/NEJMoa1716153
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
pubmed: 33301246
doi: 10.1056/NEJMoa2034577
Buschmann, M.D. et al. Nanomaterial delivery systems for mRNA vaccines. Vaccines, 9, 65 https://doi.org/10.3390/vaccines9010065 (2021).
Laczko, D. et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity 53, 724–732 e7 (2020).
pubmed: 32783919
pmcid: 7392193
doi: 10.1016/j.immuni.2020.07.019
Awasthi, S. et al. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol, 2019. 4.
Alonso, P. L. et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364, 1411–20 (2004).
pubmed: 15488216
doi: 10.1016/S0140-6736(04)17223-1
Venkataraman, C. et al. Repression of IL-4-induced gene expression by IFN-gamma requires Stat1 activation. J. Immunol. 162, 4053–61 (1999).
pubmed: 10201928
doi: 10.4049/jimmunol.162.7.4053
Apte, S. H. et al. IFN-gamma inhibits IL-4-induced type 2 cytokine expression by CD8 T cells in vivo and modulates the anti-tumor response. J. Immunol. 185, 998–1004 (2010).
pubmed: 20562261
doi: 10.4049/jimmunol.0903372
Djuretic, I. M. et al. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat. Immunol. 8, 145–53 (2007).
pubmed: 17195845
doi: 10.1038/ni1424
Wurtz, O., Bajenoff, M. & Guerder, S. IL-4-mediated inhibition of IFN-gamma production by CD4+ T cells proceeds by several developmentally regulated mechanisms. Int. Immunol. 16, 501–8 (2004).
pubmed: 14978023
doi: 10.1093/intimm/dxh050
Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571 (2020).
pubmed: 32756549
pmcid: 7581537
doi: 10.1038/s41586-020-2622-0
Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544–1555 (2020).
pubmed: 32722908
doi: 10.1056/NEJMoa2024671
Lederer, K. et al. SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation. Immunity 53, 1281–1295 e5 (2020).
pubmed: 33296685
pmcid: 7680029
doi: 10.1016/j.immuni.2020.11.009
Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594–599 (2020).
pubmed: 32998157
doi: 10.1038/s41586-020-2814-7
Moon, H. B. et al. Regulation of IgG1 and IgE synthesis by interleukin 4 in mouse B cells. Scand. J. Immunol. 30, 355–61 (1989).
pubmed: 2789429
doi: 10.1111/j.1365-3083.1989.tb01221.x
Snapper, C. M. & Paul, W. E. B cell stimulatory factor-1 (interleukin 4) prepares resting murine B cells to secrete IgG1 upon subsequent stimulation with bacterial lipopolysaccharide. J. Immunol. 139, 10–7 (1987).
pubmed: 3495594
doi: 10.4049/jimmunol.139.1.10
Bouharoun-Tayoun, H. & Druilhe, P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect. Immun. 60, 1473–81 (1992).
pubmed: 1548071
pmcid: 257020
doi: 10.1128/iai.60.4.1473-1481.1992
Coutelier, J. P. et al. Virally induced modulation of murine IgG antibody subclasses. J. Exp. Med. 168, 2373–8 (1988).
pubmed: 3199074
doi: 10.1084/jem.168.6.2373
Coutelier, J. P. et al. IgG2a restriction of murine antibodies elicited by viral infections. J. Exp. Med. 165, 64–9 (1987).
pubmed: 3794607
doi: 10.1084/jem.165.1.64
Huber, V. C. et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccin. Immunol. 13, 981–90 (2006).
doi: 10.1128/CVI.00156-06
Rostamian, M. et al. Lower levels of IgG1 in comparison with IgG2a are associated with protective immunity against Leishmania tropica infection in BALB/c mice. J. Microbiol. Immunol. Infect. 50, 160–166 (2017).
pubmed: 26066544
doi: 10.1016/j.jmii.2015.05.007
Ubillos, I. et al. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children. BMC Med. 16, 197 (2018).
pubmed: 30376866
pmcid: 6208122
doi: 10.1186/s12916-018-1186-4
White, W. I., Evans, C. B. & Taylor, D. W. Antimalarial antibodies of the immunoglobulin G2a isotype modulate parasitemias in mice infected with Plasmodium yoelii. Infect. Immun. 59, 3547–54 (1991).
pubmed: 1894361
pmcid: 258919
doi: 10.1128/iai.59.10.3547-3554.1991
Marques-da-Silva, C., Peissig, K. & Kurup, S. P. Pre-erythorocytic vaccines against malaria. Vaccines 8, 400 https://doi.org/10.3390/vaccines8030400 2020.
Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–40 (2008).
pubmed: 18797453
doi: 10.1038/mt.2008.200
Chatterjee, S. & Pal, J. K. Role of 5’- and 3’-untranslated regions of mRNAs in human diseases. Biol. Cell 101, 251–62 (2009).
pubmed: 19275763
doi: 10.1042/BC20080104
Gilbert, W. V., Bell, T. A. & Schaening, C. Messenger RNA modifications: form, distribution, and function. Science 352, 1408–12 (2016).
pubmed: 27313037
pmcid: 5094196
doi: 10.1126/science.aad8711
Sergeeva, O. V., Koteliansky, V. E. & Zatsepin, T. S. mRNA-Based therapeutics—advances and perspectives. Biochemistry 81, 709–22 (2016).
pubmed: 27449617
Zeng, C. et al., Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo. Adv. Mater. 32, e2004452. https://doi.org/10.1002/adma.202004452 (2020).
Angov, E., Legler, P. M. & Mease, R. M. Adjustment of codon usage frequencies by codon harmonization improves protein expression and folding. Methods Mol. Biol. 705, 1–13 (2011).
pubmed: 21125377
doi: 10.1007/978-1-61737-967-3_1
Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569–1584 (2020).
pubmed: 32359470
doi: 10.1016/j.ymthe.2020.04.018
pmcid: 7335735
Baiersdorfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019).
pubmed: 30933724
pmcid: 6444222
doi: 10.1016/j.omtn.2019.02.018
Kang, S. Y. et al. A novel regulatory element (E77) isolated from CHO-K1 genomic DNA enhances stable gene expression in Chinese hamster ovary cells. Biotechnol. J. 11, 633–41 (2016).
pubmed: 26762773
pmcid: 5067685
doi: 10.1002/biot.201500464
Triller, G. et al. Natural parasite exposure induces protective human anti-malarial antibodies. Immunity 47, 1197–1209 e10 (2017).
pubmed: 29195810
pmcid: 5738265
doi: 10.1016/j.immuni.2017.11.007
Tewari, R. et al. Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. J. Biol. Chem. 277, 47613–8, https://doi.org/10.1074/jbc.M208453200 (2002).
doi: 10.1074/jbc.M208453200
pubmed: 12244064
Porter, M. D. et al. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint. Clin. Vaccin. Immunol. 20, 803–10 (2013).
doi: 10.1128/CVI.00066-13
Ozaki, L. S., Gwadz, R. W. & Godson, G. N. Simple centrifugation method for rapid separation of sporozoites from mosquitoes. J. Parasitol. 70, 831–3 (1984).
pubmed: 6150971
doi: 10.2307/3281779
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–5 (2012).
pubmed: 22930834
pmcid: 5554542
doi: 10.1038/nmeth.2089
Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570–8 (2013).
pubmed: 23799535
pmcid: 3734658
doi: 10.1038/mt.2013.124
Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. Engl. 51, 8529–33 (2012).
pubmed: 22782619
pmcid: 3470698
doi: 10.1002/anie.201203263
Leung, A. K. et al. Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. J. Phys. Chem. B 119, 8698–706 (2015).
pubmed: 26087393
doi: 10.1021/acs.jpcb.5b02891
Chaudhury, S. et al. The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity. Malar. J. 15, (2016).
Schwenk, R. et al. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. PLoS ONE 9, e111020 (2014).
pubmed: 25343487
pmcid: 4208815
doi: 10.1371/journal.pone.0111020
Zou, X. et al. Towards an optimized inhibition of liver stage development assay (ILSDA) for Plasmodium falciparum. Malar. J. 12, 394 (2013).
pubmed: 24191920
pmcid: 3831258
doi: 10.1186/1475-2875-12-394